| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Impairment of goodwill and intangible assets | - | - | - | 131,595 |
| Revenues | 52,031 | 63,249 | 61,898 | 67,057 |
| Partner share and other third-party costs | 22,001 | 27,103 | 29,450 | 30,675 |
| Delivery costs | 5,730 | 6,883 | 7,288 | 7,830 |
| Sales and marketing expense | 7,865 | 11,335 | 12,754 | 13,163 |
| Research and development expense | 8,799 | 11,295 | 11,706 | 13,194 |
| General and administrative expense | 10,854 | 12,905 | 13,778 | 12,076 |
| Acquisition, integration and divestiture costs | 0 | 0 | - | - |
| Change in contingent consideration | 0 | 42 | 60 | 100 |
| Impairment of goodwill and intangible assets | 58,843 | - | - | - |
| Gain (loss) on disposition of business | - | - | 5,350 | - |
| Loss (gain) on disposal or divestiture | -320 | -200 | - | - |
| Depreciation and amortization expense | 6,473 | 6,275 | 6,291 | 6,970 |
| Total costs and expenses | 120,885 | 76,038 | 75,977 | 215,603 |
| Operating loss | -68,854 | -12,789 | -14,079 | -148,546 |
| Interest expense, net | -2,007 | -1,943 | -1,830 | -1,479 |
| Foreign currency (loss) gain | -1,812 | 5,449 | 2,627 | 4,843 |
| Gain on debt extinguishment | 0 | 0 | - | - |
| Total other (expense) income | -3,819 | 3,506 | 797 | 3,364 |
| Loss before income taxes | -72,673 | -9,283 | -13,282 | -145,182 |
| Net income (loss) attributable to parent, total | -72,673 | -9,283 | -13,282 | -145,182 |
| Net loss per share attributable to common stockholders, basic (in usd per share) | -1.36 | -0.18 | -0.26 | -2.9 |
| Net loss per share attributable to common stockholders, diluted (in usd per share) | -1.36 | -0.18 | -0.26 | -2.9 |
| Weighted-average common shares outstanding, basic (in shares) | 53,493,000 | 52,750,000 | 51,863,000 | 50,028,000 |
| Weighted-average common shares outstanding, diluted (in shares) | 53,493,000 | 52,750,000 | 51,863,000 | 50,028,000 |
Cardlytics, Inc. (CDLX)
Cardlytics, Inc. (CDLX)